Bergen, NORWAY, Oct. 9, 2018 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO) announces that the company and its collaborators willpresent interim clinical and biomarker data from its Phase II clinical programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor at the ESMO 2018 Congress in Munich (19 - 23 October 2018).
The posters will be made available at www.bergenbio.com in the Investors / Presentations section at the time of presentation and full abstracts will be made available online according to ESMO's embargo schedule: https://www.esmo.org/Conferences/ESMO-2018-Congress/Abstracts
Poster presentations at ESMO:
Sunday 21 October, 11:15 - 12:15, Hall B3 - Room 21
Predictive and Pharmacodynamic Biomarkers Associated with Phase II, selective and orally bioavailable AXL Inhibitor Bemcentinib Across Multiple Clinical Trials
Sunday 21 October, 12:45 – 13:45, Hall A3 - Poster Area
Update on the randomised Phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma
Sunday 21 October, 16:30 - 17:45, Hall B3 - Room 21
The identification of the AXL/Gas6 signalling axis as a key player of myelodysplastic syndrome (MDS) and the potential of the oral selective AXL inhibitor bemcentinib in the treatment of MDS
About the ESMO Congress
The ESMO Congress is the leading European meeting for medical oncology convening over 20,000 international delegates from the field. ESMO 2018 will be held in Munich, Germany 19– 23 October 2018.
About BerGenBio's Companion Diagnostics programme
In parallel with its phase II clinical trial programme, BerGenBio explores predictive biomarker candidates with the aim to develop a companion diagnostic to identify patients most likely to benefit from bemcentinib treatment.
Thus far, the company reported strong correlation with response of both plasma soluble AXL levels and the presence of tissue AXL in relapsed/refractory AML or MDS and advanced NSCLC, respectively.
About the BGBIL006 trial
Melanoma is the most serious type of skin cancer as it may spread to lymph nodes and distant organs if not discovered in time. Melanoma occurs when the cells that colour the skin, the so-called melanocytes, start to divide uncontrollably.
The BGBIL006 trial is a randomised Phase 1b/2 investigator sponsored clinical study of bemcentinib (BGB324) in combination with either the MAPK inhibitors MEKINIST® (trametinib) plus TAFINLAR® (dabrafenib) or the immune checkpoint inhibitor KEYTRUDA® (pembrolizumab) in patients with advanced melanoma.
For more information please access trial NCT02872259at www.clinicaltrials.gov.
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for advanced and aggressive cancers. The company's proprietary lead candidate, bemcentinib, is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme. Ongoing clinical trials are investigating bemcentinib in multiple solid and haematological tumours, in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy), and as a single agent.
In parallel, BerGenBio is developing a companion diagnostics test to identify patient populations most likely to benefit from bemcentinib: this is expected to facilitate more efficient registration trials and support a precision medicine-based commercialisation strategy.
BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). www.bergenbio.com
AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms that drive aggressive and life-threatening diseases. In cancer, AXL drives tumour survival, treatment resistance and spread, as well as suppressing the body's immune response to tumours. AXL expression has been established as a negative prognostic factor in many cancers. AXL inhibitors, therefore, have potential value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities.
Richard GodfreyCEO, BerGenBio ASA+47-917-86-304
Rune Skeie, CFO, BerGenBio ASArune.firstname.lastname@example.org+47-917-86-513
International Media Relations
David Dible, Mark Swallow, Marine Perrier, Citigate Dewe Rogersonbergenbio@citigatedewerogerson.com+44-207-638-9571
Media Relations in Norway
Jan Petter Stiff, Crux Advisersstiff@crux.no+47-995-13-891
Forward looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
This information was brought to you by Cision http://news.cision.com
View original content:http://www.prnewswire.com/news-releases/bergenbio-to-present-interim-phase-ii-clinical-preclinical-and-biomarker-data-with-selective-axl-inhibitor-bemcentinib-at-esmo-300727499.html
SOURCE BerGenBio ASA
Subscribe to our Free Newsletters!
Fennel seeds are a must-have in almost every Indian kitchen due to its health quotient. Here are a ...
True vertigo is a severe form of dizziness that is a movement hallucination. Try out some of these ...
Oxidative stress is a form of injury to body tissues due to increase in free radicals. If the ...View All